-
Inheriting the essence, keeping integrity and innovation-Liu Qingquan, one of the series of reports on the anti-epidemic report of TCM: Let the development of TCM enter a new era
Time of Update: 2021-06-04
” In conjunction with the treatment of the new crown epidemic, Liu Qingquan, Dean of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, said when talking about his experience, the integration of Chinese and Western medicine is very important for the development of Chinese medicine, and it may be possible in the future.
-
The picture shows the new crown vaccine: How to protect against the Dragon Boat Festival?
Time of Update: 2021-06-04
In case of sudden major changes, Zhang Yuntao mentioned that the development of vaccines in my country will be very timely and can also meet the needs of the broad masses of people under the conditions of mutations.
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Ginkgo Damo Injection
Time of Update: 2021-06-02
The holder of the drug marketing authorization shall conduct in-depth research on the mechanism of new adverse reactions, take effective measures to conduct publicity and training on the use and safety issues, and immediately notify the drug dealer and user unit of the content change involving drug safety in an appropriate manner.
-
The global nasal polyp treatment market has a CAGR of 5%. Merck, Sanofi, etc. participate in the competition
Time of Update: 2021-06-02
From 2019 to 2027, the nasal polyp treatment market in the Asia-Pacific region is expected to grow at a high compound annual growth rate of 6% due to the surge in the number of target patients suffering from inflammatory respiratory diseases, which is likely to promote the inclusion of India and The number of nasal polyps treatment operations in emerging markets including China has increased.
-
Zhejiang Pharmaceutical Levofloxacin Tablets Obtained Drug Registration Certificate
Time of Update: 2021-06-02
25g for levofloxacin tablets approved and issued by the National Medical Products Administration.
5g specification approved manufacturers include Daiichi Sankyo Pharmaceutical (Beijing) Co.
S. dollars; data query in Minai shows that domestic sales of levofloxacin tablets in 2020 will be 1.
-
Eisai financial report: China continues to grow lenvatinib and perampanel into national health insurance
Time of Update: 2021-06-02
In addition, the sales of Eisai's blockbuster oncology drug Lenvima (lenvatinib) have also declined in Japan, but have maintained a growth trend in the United States, China and other regions.
-
Shanghai Pharmaceuticals SPH3127 Tablets New Indication Approved for Clinical Clinic
Time of Update: 2021-06-02
On May 19, Shanghai Pharmaceuticals issued an announcement stating that the clinical trial application for the development of "SPH3127 tablets" for chronic kidney disease indications was officially accepted by the State Food and Drug Administration.
-
After Biotech’s failure, the domestic Trop-2 ADC drug reported to be launched...
Time of Update: 2021-06-02
On May 12, the CDE official website showed that Genting Pharmaceuticals submitted a listing application for Trop-2 ADC product-Trodelvy (gosartuzumab for injection) for metastatic triple-negative breast cancer that has received at least 2 therapies in the past (MTNBC) Adult patients.
-
Haisco medium and long chain fat emulsion/amino acid (16)/glucose (16%) injection review
Time of Update: 2021-06-02
The long-chain fat emulsion/amino acid (16)/glucose (16%) injection developed by the generic drug product obtained the drug registration approval issued by the National Medical Products Administration in July 2018 (batch number: 2018S00429).
-
Arnold Pharma submits clinical application for new drug AN4005 to FDA
Time of Update: 2021-06-02
On May 20, Arnold Pharma announced that it had submitted a clinical trial application (IND) for its original innovative drug oral PD-L1 inhibitor AN4005 to the US FDA.
-
44 batches of drugs have been seized for clofenaceous tablets, Huoxue Zhuanggu pills...
Time of Update: 2021-06-02
The announcement pointed out that the Hubei Provincial Drug Administration has instructed relevant departments to take necessary control measures such as seizures, seizures, suspension of sales, and recalls for drugs that do not meet the requirements of the inspection, and investigate and deal with the production enterprises and the sampled units in accordance with relevant laws and regulations.
-
New regulations | Eight considerations for the construction of the MAH pharmacovigilance system
Time of Update: 2021-06-02
In the draft of the "Pharmacological Vigilance Quality Management Regulations" released in 2020, it is required that the person in charge of pharmacovigilance should be the senior management of the enterprise; in the current finalized document, the word "high-level" has been deleted.
-
Shanghai Pharmaceuticals: Simvastatin tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-06-02
On May 18, Shanghai Pharmaceuticals announced that Xinyi Wanxiang, a subsidiary of the company, recently received the "Drug Supplementary Application Approval Notice" issued by the State Food and Drug Administration on simvastatin tablets (10mg, 20mg), and the drug passed Consistency evaluation of the quality and efficacy of generic drugs.
-
The first EZH2 inhibitor approved by the FDA is applied for clinical application in China
Time of Update: 2021-06-02
The results of the study showed that the ORR of Tazemetostat in EZH2 mutant patients was 69%, of which CR was 12%, PR was 57%, and mDOR was 10.
-
What is the difference between Guipi Pill and Jianpi Pill?
Time of Update: 2021-06-02
After the summer, many people lose their appetite, feel fatigued, and often experience symptoms such as heart palpitations, shortness of breath, insomnia, and dreams.
The Chinese patent medicine Guipi Pill and Jianpi Pill are the two most commonly used drugs for the above symptoms in summer.
-
Immunotherapy reduces the risk of recurrence of lung cancer
Time of Update: 2021-06-02
On May 20, Roche announced that its blockbuster PD-L1 inhibitor Tecentriq, as an adjuvant therapy, has achieved positive results in a pivotal phase 3 clinical trial for the treatment of early stage NSCLC patients.
-
BeiGene's BTK Inhibitor New Indications Marketing Application Accepted by FDA
Time of Update: 2021-06-02
It is reported that the application is mainly based on the results of a single-arm, open, multi-center phase 2 MAGNOLIA clinical trial of zebutinib for the treatment of patients with relapsed or refractory MZL, and a zebutinib against B-cell malignancies Supporting data from the global Phase 1/2 clinical trials.
-
No prescription for online prescription?
Time of Update: 2021-06-01
Some prescription drugs need to be selected according to the patient's physiological state, or some special inspections are required before and after the medication, such as antihypertensive drugs and the drugs for the treatment of hypothyroidism purchased by the Beijing Youth Daily reporter during the investigation.
-
AstraZeneca's new crown vaccine Vaxzevria approved in Japan for people 18 years and older
Time of Update: 2021-06-01
Recently, AstraZeneca announced that its COVID-19 vaccine Vaxzevria (ChAdOx1-S [recombinant], formerly known as AZD1222) has been approved for emergency use in Japan for active immunization of people aged 18 and over.
-
Bayer's 4 billion anti-thrombotic drugs are in a hurry!
Time of Update: 2021-06-01
On May 24, the official website of the State Food and Drug Administration showed that five companies including Qilu Pharmaceutical, Dongguan Yangzhikang Pharmaceutical, and Hunan Jiudian Pharmaceutical were approved for listing on the same day as Rivaroxaban tablets.
